• +1-646-491-9876
    • +91-20-67278686

    Search

    Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Review H1 2017

    Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Review H1 2017

    • Report Code ID: RW0001851080
    • Category Life Sciences
    • No. of Pages 112
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H1 2017

    Summary

    Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Nuclear factor (erythroid-derived 2) -like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.

    Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) pipeline Target constitutes close to 36 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 4, 13 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 8 and 3 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Metabolic Disorders, Cardiovascular, Ophthalmology, Toxicology, Infectious Disease, Respiratory, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Inflammation, Multiple Sclerosis, Psoriasis, Friedreich Ataxia, Type 2 Diabetes, Amyotrophic Lateral Sclerosis, Cardiomyopathy, Chagas Disease (American Trypanosomiasis) , Chronic Obstructive Pulmonary Disease (COPD) , Diabetic Complications, Diabetic Nephropathy, Medulloblastoma, Neuroblastoma, Radiodermatitis, Systemic Sclerosis (Scleroderma) , Type 1 Diabetes (Juvenile Diabetes) , Age Related Macular Degeneration, AIDS Associated Dementia, Alport Syndrome, Alzheimer's Disease, Atherosclerosis, Breast Cancer, Cardiovascular Disease, Cerebral Vasospasm, Chronic Kidney Disease (Chronic Renal Failure) , Corneal Degeneration, Encephalomyelitis, Huntington Disease, Idiopathic Pulmonary Hypertension, Ischemia Reperfusion Injury, Metastatic Breast Cancer, Metastatic Melanoma, Mitochondrial Diseases, Neuro Muscular Disorders, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Post-Myocardial Infarction, Primary Progressive Multiple Sclerosis (PPMS) , Prostate Cancer, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Radiation Injury, Relapsing Remitting Multiple Sclerosis (RRMS) , Retinal Degeneration, Retinopathy, Subarachnoid Hemorrhage and Ulcerative Colitis.

    The latest report Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H1 2017, outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
    - The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Overview
    Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Companies Involved in Therapeutics Development
    Arbor Pharmaceuticals LLC
    Bayer AG
    BioApex sro
    Biogen Inc
    C4X Discovery Holdings PLC
    Catabasis Pharmaceuticals Inc
    Daiichi Sankyo Company Ltd
    Evgen Pharma Plc
    Ixchel Pharma LLC
    Jiangsu Hengrui Medicine Co Ltd
    Mochida Pharmaceutical Co Ltd
    Reata Pharmaceuticals Inc
    Rigel Pharmaceuticals Inc
    vTv Therapeutics Inc
    Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Drug Profiles
    BA-1521 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bardoxolone methyl - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CAT-4001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DH-404 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dimethyl fumarate DR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IXC-103 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IXC-105 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LH-503 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LH-526 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MG-132 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MIND-4 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    monosodium luminol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nifurtimox - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nifurtimox SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    omaveloxolone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    R-970 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RS-9 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RTI-79 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SFX-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SFX-02 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SFX-03 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Activate Nrf2 for Inflammation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Activate Nrf2 for Inflammation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Target NRF2 and BACH1 for Parkinson's Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules 2 to Activate Nrf2 for Oncology and Inflammation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Activate NRF-2 for COPD - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Activate Nrf2 for Oncology and Inflammation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit GSK3B and Activate Nrf2 for Alzheimer's Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TBE-31 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TFM-735 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    trigonelline hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VCB-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VCB-102 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VEDA-1209 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    XP-23829 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Dormant Products
    Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Discontinued Products
    Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Product Development Milestones
    Featured News & Press Releases
    Jun 01, 2017: Reata Pharmaceuticals Announces Positive Data From Part One of Moxie Trial of Omaveloxolone for Friedreich's Ataxia
    Apr 24, 2017: TECFIDERA Data Demonstrates Improved Outcomes with Early MS Treatment at American Academy of Neurology in Boston
    Apr 18, 2017: Biogen Highlights Data on TECFIDERA at AAN Congress
    Mar 31, 2017: Forward Pharma Intends to Appeal Decision in Patent Interference Proceeding with Biogen
    Mar 28, 2017: Evgen Pharma: Further US Patent Grant
    Feb 23, 2017: Reata Announces Initiation of Phase 2/3 Study of Bardoxolone Methyl in the Treatment of Chronic Kidney Disease Due to Alport Syndrome
    Feb 14, 2017: Evgen Pharma Announces Patent Grant in the United States
    Feb 13, 2017: Evgen Pharma Announces Services Agreement with Drug Development Consortium
    Jan 17, 2017: Evgen Pharma Announces First Patient Dosed in Phase II Breast Cancer Trial
    Jan 11, 2017: Evgen Pharma Receives Positive DSMB Review of SAS Trial
    Nov 29, 2016: Hardman Research: Clinical potential of sulforaphane
    Nov 17, 2016: Catabasis Pharmaceuticals Provides Update on Rare Disease Program CAT-4001 at Investor Day
    Nov 16, 2016: New Pre-Clinical Data on a vTv Therapeutics Small Molecule Drug Candidate Against Parkinson's Disease to be Presented at the Society for Neuroscience 2016 Meeting in San Diego
    Nov 15, 2016: Bayer to Fight Chagas Disease in Children
    Nov 14, 2016: Reata Announces Plan for Global Phase 2/3 Trial in Chronic Kidney Disease Caused by Alport Syndrome
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Arbor Pharmaceuticals LLC, H1 2017
    Pipeline by Bayer AG, H1 2017
    Pipeline by BioApex sro, H1 2017
    Pipeline by Biogen Inc, H1 2017
    Pipeline by C4X Discovery Holdings PLC, H1 2017
    Pipeline by Catabasis Pharmaceuticals Inc, H1 2017
    Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Pipeline by Evgen Pharma Plc, H1 2017
    Pipeline by Ixchel Pharma LLC, H1 2017
    Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
    Pipeline by Mochida Pharmaceutical Co Ltd, H1 2017
    Pipeline by Reata Pharmaceuticals Inc, H1 2017
    Pipeline by Rigel Pharmaceuticals Inc, H1 2017
    Pipeline by vTv Therapeutics Inc, H1 2017
    Dormant Products, H1 2017
    Dormant Products, H1 2017 (Contd..1) , H1 2017
    Dormant Products, H1 2017 (Contd..2) , H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Arbor Pharmaceuticals LLC
    Bayer AG
    BioApex sro
    Biogen Inc
    C4X Discovery Holdings PLC
    Catabasis Pharmaceuticals Inc
    Daiichi Sankyo Company Ltd
    Evgen Pharma Plc
    Ixchel Pharma LLC
    Jiangsu Hengrui Medicine Co Ltd
    Mochida Pharmaceutical Co Ltd
    Reata Pharmaceuticals Inc
    Rigel Pharmaceuticals Inc
    vTv Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//nuclear-factor-erythroid-2-related-factor-2-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//nuclear-factor-erythroid-2-related-factor-2-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//nuclear-factor-erythroid-2-related-factor-2-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments